France Medical Cannabis Market, by Route of Administration

Growth Outlook

• The France Medical Cannabis Market, by Route of Administration market is on a steady long-term growth path. Segment value stands at roughly USD 1083 Mn in 2026 and is projected to reach USD 1474 Mn by 2027 — a gain of about 36% over the forecast period, translating to a CAGR in the double digits.
• What the regional split looks like (2026): Inhalation leads, holding roughly 58% of segment value — the single largest regional share. Oral is the second-largest contributor. Topical make up the remainder, in descending order.
• By 2027, Inhalation alone is expected to reach USD 852 Mn, with Oral at USD 411 Mn.

Market Dynamics

The demand for medical cannabis in France has been growing steadily in recent years, and it is expected to continue to rise in the coming years. This demand is largely driven by the increasing acceptance and recognition of cannabis as a potential treatment option for various medical conditions.

One of the key factors driving the demand for medical cannabis in France is the current restrictions on its use. Currently, medical cannabis is only available in France through the pharmaceutical route, meaning it can only be prescribed by a doctor and can only be obtained from a pharmacy. This limits access to the drug, as many patients may not have access to a prescribing doctor or may face barriers in obtaining the drug from a pharmacy.

In addition, the pharmaceutical route of administration also limits the variety and forms of medical cannabis available. Currently, there are only two approved medical cannabis products in France – Sativex and Marinol. These products are primarily used for treating spasticity associated with multiple sclerosis, and are only available in oral spray and capsule forms. This restricts the ability of patients to choose a preferred route of administration that may be more suitable for their individual needs.

This has led to a growing demand for alternative routes of administration for medical cannabis in France. Many patients and medical professionals are advocating for the legalization of alternative forms of medical cannabis, such as oils, tinctures, and inhalation methods like vaporization. These alternative forms can offer a more precise and efficient way of administering the drug, as well as expanding the range of conditions that can be treated with medical cannabis.

The demand for alternative routes of administration is also driven by the fact that many patients may not be comfortable with the psychoactive effects of cannabis when consumed orally. They may prefer non-psychoactive forms such as oils or topicals, which can provide therapeutic benefits without the psychoactive effects.

Furthermore, the demand for alternative routes of administration is not only limited to patients. There is also a growing demand from medical professionals for greater flexibility in prescribing medical cannabis. Many doctors believe that having a wider range of forms and routes of administration would allow them to tailor treatment plans to individual patients and their specific medical conditions.

In conclusion, the demand for medical cannabis in France continues to grow as patients and medical professionals seek alternative routes of administration for a wider variety of medical conditions. The current restrictions and limited options have led to a push for more inclusive policies and regulations to meet the evolving needs and preferences of patients and the medical community.